Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

This week in Drug Discovery (16 – 20 March) 

Published

on

News round-up for 16 – 20 March February by Bruno Quinney, Content Team at DDW. 

This week, a pioneering method is being used to make drugs for Parkinson’s disease. Elsewhere, advances have been made in both research and trials for common cancers. 

The top stories: 

 

Edinburgh team makes Parkinson’s drug from plastic bottles 


A drug to treat Parkinson’s disease can be made from waste plastic bottles using a pioneering method, a study shows.

Read more… 

Cancer enzyme discovery opens new avenues for drug discovery 


Researchers have identified the enzyme DHX8 as a crucial regulator of the stress response protein HSF1, which may have potential to open new avenues for future drug development. 
 

Read more… 

 

Research identifies new target for multiple myeloma treatment 


New research 
published in the Clinical Lymphoma, Myeloma & Leukemia journal has confirmed that Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) are promising therapeutic targets for the treatment of multiple myeloma.  

Read more… 

 

 

First patient dosed in ROR1-positive blood cancer treatment 


The first patient has been dosed with NVG-222, a treatment for ROR1-positive blood cancers developed by biotechnology company NovalGen.  

Read more… 

 

 

Rare disease drugs to generate $400bn by 2032, report reveals  

Evaluate’s ‘2026 Orphan Drug Report’ predicts the sales of orphan drugs will continue to rise steadily, despite policy changes and pricing turmoil. According to the forecast, orphan drugs will account for over 21% of all prescription pharmaceutical drugs by 2032. 

Read more… 

 

 

 

 

 

 

 

 

 

 

 

 

 

The post This week in Drug Discovery (16 – 20 March)  appeared first on Drug Discovery World (DDW).

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Federal government could improve infectious disease monitoring, says federal government

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

What dish will health secretary Robert F. Kennedy Jr. make on the first episode of his new cooking show? Wrong answers only.

Read the rest…

Read More

Published

on

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

What dish will health secretary Robert F. Kennedy Jr. make on the first episode of his new cooking show? Wrong answers only.

Read the rest…

Read More

Continue Reading

Uncategorized

Opinion: What a recent op-ed got wrong about our Covid study

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others.

To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them. You can submit a Letter to the Editor here, or find the submission form at the end of any First Opinion essay.

Read the rest…

Read More

Published

on

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others.

To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them. You can submit a Letter to the Editor here, or find the submission form at the end of any First Opinion essay.

Read the rest…

Read More

Continue Reading

Uncategorized

Spatiotemporal Multiomics Charts Cellular Dynamics of Liver Metastasis

Published

on

Metastasis remains one of cancer’s most difficult biological transitions to capture: tumor cells must leave a primary tumor, survive circulation, enter a distant organ, and then either disappear, persist, or eventually grow into clinically detectable lesions. A spatiotemporal study in mice and human samples identifies transient tumor-cell and immune-niche states that may offer windows for intercepting metastatic colonization.

A new study published in Science provides a high-resolution look at that process in liver cancer, suggesting that metastatic colonization unfolds through ordered changes in both disseminated tumor cells and the immune microenvironments that surround them.

In the study, “Spatiotemporal multiomics uncover tumor ecosystem dynamics during metastatic colonization,” researchers led by Yunfan Sun, MD, PhD, at Zhongshan Hospital, Fudan University, applied spatiotemporal multiomics to experimental hepatocellular carcinoma mouse models and human metastatic samples. Their goal was to reconstruct how disseminated tumor cells, or DTCs, survive the earliest stages of lung colonization and later transition into metastatic outgrowth.

The team integrated high-resolution spatial transcriptomics, single-cell RNA sequencing, and chromatin-accessibility profiling across nine sequential stages of lung colonization in mouse models. The resulting atlas followed liver cancer cells from their first arrival in the lungs through later metastatic progression, while also mapping changes in nearby immune cells.

The analysis indicated that early metastatic seeding is not simply a random survival event. “After a massive innate immune clearance, primarily by neutrophils and natural killer (NK) cells, a rare subpopulation of DTCs survived by entering a transient, quiescent Phgdhhigh state,” the authors write. These cells were associated with an immune-scarce niche, allowing them to avoid elimination during a vulnerable early window.

Mechanistically, the authors linked this state to metabolic and epigenetic remodeling. Alveolar type 2 cells enriched near surviving DTCs appeared to promote the Phgdhhigh phenotype. Elevated PHGDH activity fueled one-carbon metabolism and increased levels of S-adenosylmethionine (SAM). That shift was tied to H3K27me3-mediated silencing of proinflammatory chemokine genes, including Ccl2 and Cxcl10, which would otherwise help recruit immune cells to the niche.

Perturbing this axis genetically or pharmacologically restored chemokine expression, increased immune surveillance, and reduced metastatic outgrowth in the models, according to the study. Lineage-tracing experiments further suggested that many macrometastases derived from ancestors that had passed through the transient Phgdhhigh state.

The researchers also identified a second niche-remodeling step before rapid metastatic expansion. At this stage, Cx3cr1high interstitial macrophages accumulated in the DTC niche. These “macrophages recruited immunosuppressive cells (T regulatory cells, neutrophils, and alveolar macrophages) and provided growth signals through the IGF1-IGF1R axis that trigger the transition of DTCs from quiescence to rapid proliferation,” the authors report in the study. Depleting these macrophages reduced metastatic burden in mouse experiments.

Together, the findings point to metastatic colonization as a temporally organized process shaped by reciprocal interactions between tumor cells and their local microenvironment. First, a rare tumor-cell state helps establish early immune evasion. Later, macrophage-driven remodeling appears to convert a quiescent niche into one that supports metastatic outgrowth.

Although the work is largely preclinical, the authors suggest that these transient states may represent vulnerabilities for micrometastasis-targeting approaches. By defining when and how early DTCs evade immune attack, the study offers a framework for developing interventions aimed not only at established metastases, but also at the earliest stages of metastatic colonization.

The post Spatiotemporal Multiomics Charts Cellular Dynamics of Liver Metastasis appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Advertisement

Trending